Xenon Pharmaceuticals XENE Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's stock issuance proceeds?
- Xenon Pharmaceuticals (XENE) reported stock issuance proceeds of $5.49M in Q1 2026.
- How has Xenon Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Xenon Pharmaceuticals's stock issuance proceeds increased by 376.7% year-over-year, from $1.15M to $5.49M.
- What is the long-term trend for Xenon Pharmaceuticals's stock issuance proceeds?
- Over 3 years (2021 to 2025), Xenon Pharmaceuticals's stock issuance proceeds has grown at a 167.2% compound annual growth rate (CAGR), from $260K to $4.96M.
- What does stock issuance proceeds mean?
- Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.